Get the Stockscreener App
3.23
9.78%
-0.35
After Hours:
3.40
0.17
+5.26%
Atyr Pharma Inc stock is traded at $3.23, with a volume of 1.17M.
It is down -9.78% in the last 24 hours and up +23.28% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$3.58
Open:
$3.53
24h Volume:
1.17M
Relative Volume:
0.84
Market Cap:
$300.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.44%
1M Performance:
+23.28%
6M Performance:
-0.62%
1Y Performance:
+0.00%
1-Day Range:
$3.22
$3.57
1-Week Range:
$3.22
$3.67
52-Week Range:
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
3.23 | 300.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
aTyr Pharma, Inc.'s (NASDAQ:ATYR) Path To Profitability - simplywall.st
Wells Fargo & Company MN Invests $383,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
FY2026 EPS Estimates for Atyr PHARMA Lowered by Analyst - Defense World
Atyr Pharma Inc [ATYR] Records 200-Day SMA of $2.90 - knoxdaily.com
There is no doubt that Atyr Pharma Inc (ATYR) ticks all the boxes. - Sete News
How should investors view Atyr Pharma Inc (ATYR)? - uspostnews.com
JPMorgan Chase & Co. Boosts Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Preclinical Data for NRP2-Targeting - GlobeNewswire
When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit? - Yahoo
Leerink Partners gives an Outperform recommendation for Atyr Pharma Inc (ATYR) - knoxdaily.com
aTyr Pharma presents preclinical data on ATYR2810 at AACR - TipRanks
aTyr Pharma (ATYR) Reveals Promising Preclinical Data on Cancer Treatment | ATYR Stock News - GuruFocus
Market Watch Highlights: Atyr Pharma Inc (ATYR) Ends on an Downturn Note at 3.27 - DWinneX
Atyr Pharma Inc (NASDAQ: ATYR) Stock: More Upside Ahead? - Marketing Sentinel
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Breakthrough: Novel Antibody ATYR2810 Extends Survival in Aggressive Brain Cancer Trial - Stock Titan
Geode Capital Management LLC Buys Shares of 891,407 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Director Gross Jane A acquire 3,750 shares of Atyr Pharma Inc [ATYR] - knoxdaily.com
Analytical Lens: Exploring Atyr Pharma Inc (ATYR)’s Financial Story Through Ratios - DWinneX
Atyr PHARMA (ATYR) to Release Quarterly Earnings on Thursday - Defense World
Watch this stock’s price performance: Atyr Pharma Inc (NASDAQ:ATYR) - uspostnews.com
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock By Investing.com - Investing.com Canada
Solid Biosciences (NASDAQ:SLDB) versus Atyr PHARMA (NASDAQ:ATYR) Head to Head Comparison - Defense World
Atyr Pharma Inc (ATYR) receives an Outperform rating from Leerink Partners - knoxdaily.com
Cantor maintains Overweight on aTyr Pharma stock ahead of trials By Investing.com - Investing.com Canada
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
Raymond James Financial Inc. Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Makes New $319,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR) - The AM Reporter
Atyr PHARMA INC (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
US High Growth Tech Stocks to Watch in 2023 - simplywall.st
aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire
Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):